am833 semaglutide FBI warns about counterfeit weight loss drugs PDF) Preclinical Weight Loss Efficacy

Lancet 365 , 599609

Interim data from the ESSENCE trial revealed that 62.7% of patients treated with semaglutide had improved steatohepatitis and 37% had improved liver fibrosis compared to 34.1% and 22.5%, respectively, who received placebo

10.1016/j.diabres.2023.110605 16 LiuL.ChenJ.WangL.ChenC

These results were further supported by another study from the same lab, whereby GLP-1 was shown to stimulate myocardial glucose uptake via mechanisms that were p38 MAP kinase and NO dependent, but independent of adenylyl cyclase or Akt [73]

Answer: Expect a structured evaluation first, a supervised protocol if appropriate, and ongoing monitoring